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ABSTRACT 
 
Disarmed versions of the cytotoxin ricin can deliver fused 
peptides into target cells leading to MHC class I-restricted 
antigen presentation [Smith et al. J Immunol 2002; 169:99-
107]. The ricin delivery vector must contain an attenuated 
catalytic domain to prevent target cell death, and the fused 
peptide epitope must remain intact for delivery and 
functional loading to MHC class I molecules. Expression in 
E. coli and purification by cation exchange chromatography 
of the fusion protein is described. Before used for delivery, 
the activity of the vector must be characterized in vitro, via 
an N-glycosidase assay, and in vivo, by a cytotoxicity assay. 
The presence of an intact epitope must be confirmed using 
mass spectrometry by comparing the actual mass with the 
predicted mass. 
 
INTRODUCTION 
 
Ricin, along with several protein toxins have been exploited 
for their intracellular trafficking and/or membrane 
translocation properties allowing delivery of exogenous 
peptides directly into the MHC class I processing and 
presentation pathway of target cells (1-4). Thus, ricin can be 
classified as a non-live vector, capable of delivering fused 
peptides to target cells thereby inducing a CD8
+ T cell 
response. Due to the nature of these non-live vectors, ex vivo 
application of professional antigen presenting cells (APC) 
with disarmed (inactivated) toxin vectors carrying fused 
antigens remains a long-term goal in vaccine development. 
In this way, it is envisioned that re-administration of primed 
APC could promote a protective CD8
+  T cell response.   
However, in contrast with other protein vectors described so 
far (4), we have shown that ricin can deliver peptides into 
cells in a TAP-independent manner, directly to newly 
synthesized MHC class I molecules in the ER of target cells 
(1). Indeed this strong TAP-negative bias of the ricin vector 
may pave the way for developing therapeutic vectors 
directed solely against certain TAP-negative tumours in vivo. 
 
Ricin is a heterodimeric protein composed of two subunits, 
ricin A chain (RTA) and ricin B chain (RTB), that are 
normally disulfide bonded together. RTA has an rRNA-
specific N-glycosidase activity and is therefore capable of 
inactivating cytosolic ribosomes, whilst RTB is a galactose-
specific lectin able to bind the holotoxin to the target cell 
facilitating endocytic uptake. Productive intoxication of a 
cell by ricin involves receptor-mediated uptake at the cell 
surface, retrograde routing via the Golgi complex to the 
endoplasmic reticulum (ER) lumen (5-8), followed by retro-
translocation of the catalytic subunit through Sec61 channels 
into the cytosol (9). Upon reaching the cytosol RTA evades 
proteasomal degradation (10) and is thought to undergo 
ribosome-mediated refolding to an active moiety capable of 
inactivating the very molecules that helped refold the protein 
(11). 
 
Although the retrograde transport of ricin can directly 
intersect with the MHC class I processing and presentation 
machinery in the cytosol and ER, respectively, allowing 
exogenous peptide delivery (1), there are some practical 
issues that have to be addressed when developing therapeutic 
ricin vectors. Mainly the toxicity of the vector and the 
stability of epitope within the fusion have to be considered. 
The delivery vector must therefore contain both an 
attenuated catalytic domain to prevent target cell death, and 
the fused peptide epitope must remain intact for functional 
processing and loading to MHC class I molecules. 
 Smith et al.   14 
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Here we describe the details of those methods from our 
published work as related to the expression, purification and 
characterization of potential ricin vectors for their use in 
antigen delivery (1). 
 
MATERIALS AND METHODS 
 
Cell lines 
 
MC57 cells, a C57BL/6-derived fibrosarcoma, were grown 
in RPMI 1640 (Life Technologies, Rockville, MD) 
containing 5% (v/v) FCS, 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 µg/ml streptomycin. 
 
Expression of recombinant RTA-peptide 
fusions 
 
The pUTA vector (12) containing the RTA-peptide fusion 
sequence (1) was transformed into competent E. coli JM101. 
A single transformant was used to inoculate 100 ml of 2YT 
medium (17 g/l bactotryptone, 10 g/l yeast extract, 5 g/l 
sodium chloride) containing 100 µg/ml ampicillin and this 
was grown overnight at 37ºC. This overnight culture was 
used to inoculate 2x 500 ml of 2YT which was then grown 
for 2 hours at 30ºC in an orbital shaker. Expression was 
induced by the addition of IPTG to a final concentration of 
0.1 mM and incubation was continued for a further 4 hours 
at 30ºC. Cells were harvested by centrifugation in a JA10 
rotor in a Beckman J2-21M/E centrifuge at 2740 xg (5000 
rpm) at 4ºC for 15 minutes. Cell pellets were resuspended in 
15 ml of ice-cold 5 mM sodium phosphate buffer (pH 6.5) 
(containing one Complete
TM Protease inhibitor cocktail 
tablet, Roche). Cells were lysed using a MSE Soniprep150 
sonicator at an amplitude of 15µ for 30 seconds six times 
with 30 second intervals keeping the cells chilled in an ice 
water bath at all times. Cell debris was pelleted by 
centrifugation in a JA20 rotor in a Beckman J2-21M/E 
centrifuge at 31400 xg (20000 rpm) at 4ºC for 30 minutes. 
The supernatant was transferred to a fresh tube and the 
volume made up to 50 ml with 5 mM sodium phosphate 
buffer (pH 6.5). 
 
Purification of RTA-peptide fusions 
 
RTA-peptide fusions were purified from crude E.coli lysate 
by ion-exchange chromatography at 4ºC. The freshly 
prepared soluble cell lysate containing the over-expressed 
RTA-peptide fusion was immediately loaded onto a 50 ml 
CM-Sepharose CL-6B column (pre-equilibrated with 5 mM 
sodium phosphate pH6.5) and unbound proteins were 
removed by washing with 1 litre of 5 mM sodium phosphate 
pH6.5. The column was washed with 100 ml of 100 mM 
NaCl in 5 mM sodium phosphate pH6.5 and bound proteins 
were eluted, collecting 10 ml fractions, in a linear gradient of 
100-300 mM NaCl in the same buffer, all column steps were 
performed at 4ºC with the aid of gravity. Before re-use, the 
column was stripped with a 500 ml wash of 2M NaCl in 5 
mM sodium phosphate pH6.5 and re-equilibrated with 1 litre 
of 5 mM sodium phosphate pH6.5. Fractions were assessed 
for protein content by measurement of A280 in a Shimadzu 
UV-160A spectrophotometer and aliquots of suitable 
fractions were analyzed for RTA content by 15% SDS-
PAGE and Western blotting. 
 
Reassociation and quantification of RTA-
peptide fusions 
 
(a) Reassociation of RTA with RTB 
 
Typically, 100 µg of the purified RTA-peptide fusion was 
mixed with 100 µg of RTB (Vector Laboratories) and made 
up to a final volume of 2 ml with PBS containing 100mM 
lactose and 2% β-mercaptoethanol. This was dialysed for 16 
hours against 1 litre of PBS containing 100 mM lactose and 
then a further 36 hours against 5 litres of PBS.  
 
(b) Purification of peptide containing holotoxins 
 
Reassociated holotoxin was separated away from any free 
RTA on a 0.5 ml immobilized α-lactose column (Sigma), 
which had been pre-equilibrated with PBS. The dialysate 
was cycle loaded onto the column three times and the 
column was then washed with 10 ml of PBS before eluting 
bound holotoxin (and free RTB) in 5 ml of PBS containing 
75 mM galactose. Eluted protein was dialysed for 16 hours 
against 1 litre of PBS to remove the galactose before 
quantifying protein as described below. 
 
(c) Quantification of ricin holotoxins 
 
Known quantities of RTA (in duplicate) were separated by 
reducing SDS-polyacrylamide gel electrophoresis, along 
with duplicate samples of 20 µl of the freshly reassociated 
holotoxins. Protein was visualized using a standard silver 
stain protocol and standard curve was derived from the A-
chain standards using Molecular Dynamics ImageQuant 
version 3.3.  From this the quantity of RTA in the holotoxins 
could be derived and hence the concentration of the 
reassociated holotoxin. 
 
Assay of the N-glycosidase activity of RTA-
peptide fusions 
 
(a)  Incubation of ribosomes with RTA-peptide 
fusions 
 
Typically for each reaction, 20 µg of yeast ribosomes (see 
below) were incubated at 30ºC for 1 hour with the RTA-
peptide fusion in 1x Endo buffer (25 mM Tris.Cl (pH 7.6), Smith et al.   15 
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25 mM KCl, 5 mM MgCl2) in a total volume of 20 µl. 
Reactions were stopped by the addition of 100 ml 2x Kirby 
buffer  (section f, see below) and 80 ml H2O. 
 
(b) Extraction of rRNA 
 
The rRNA was obtained by two phenol-chloroform 
extractions and rRNA was precipitated by the addition of 0.1 
volumes 2M NaOAc pH 6.0 and 2.5 volumes 100% ethanol. 
The reaction mixtures were frozen on dry ice and the 
precipitated rRNA was pelleted by centrifugation at 13000 
rpm for 30 minutes at 4ºC in a Heraeus refrigerated 
microfuge. The pellets were washed once with 70% ethanol 
and dried for 15 minutes in a vacuum dessicator. 
 
(c) Aniline treatment of rRNA 
 
The rRNA pellets were resuspended in 10 µl H2O and an 
aliquot was quantified by measuring the A260  (an A260 of 25 
is equal to 1 mg/ml rRNA). 4 µg of rRNA was treated for 2 
minutes at 60ºC with 20 µl of acetic-aniline (or 20 µl of H2O 
for non-aniline treated controls). The reactions were stopped 
by the addition of 0.1 volumes of NH4OAc and 2.5 volumes 
100% ethanol and frozen on dry ice before centrifugation for 
30 minutes at 4ºC. The pellets were washed once with 70% 
ethanol and dried in a vacuum dessicator. The pellets were 
resuspended in 15
 µl of 60% de-ionized formamide / 0.1x 
TPE (3.6 mM Tris, 3 mM NaH2PO4, 0.2 mM EDTA) mix 
and run on a denaturing formamide gel as described below. 
 
(d) Separation of rRNA by agarose-formamide gel 
electrophoresis 
 
Prepared rRNA samples were heated at 65ºC for 5 minutes 
and then cooled on ice for 5 minutes. 3 ml of sample buffer 
(50% glycerol) was added to each sample and they were 
loaded into wells of a horizontal 1.2% agarose, 0.1x TPE, 
50% de-ionized formamide gel which had been preflooded 
with 60% formamide / 0.1xTPE mix. Dye is omitted from 
the sample buffer so that any diagnostic fragment produced 
is not obscured for quantification. The samples were 
electrophoresed in 0.1x TPE at 25-28mA for 60-90 minutes 
and then stained for 15 minutes in 500 ml of water 
containing 25 µl of 10 mg/ml ethidium bromide before 
destaining in water for at least 30 minutes. The RNA was 
visualized on a short-wave ultra-violet transilluminator, and 
digital images recorded using a GDS8000 Gel 
Documentation and Analysis System (Ultra-Violet Products, 
Cambridge, UK). 
 
(e) Quantification of RNA fragments 
 
The percentage of depurination was quantified from digital 
images of ethidium bromide stained gels using Molecular 
Dynamics Imagequant version 3.3. The lengths of the aniline 
fragment (the fragment produced by ricin A-chain induced 
depurination, followed by acetic-aniline treatment) and the 
5.8S rRNA fragment are known to be 369 bases and 160 
bases respectively. The intensity of aniline band could 
therefore be quantified, using the intensity of 5.8S rRNA 
band in the same lane of the agarose-formamide gel as a 
loading control. A background value was also calculated by 
quantifying an area of the gel close to the aniline band and 
relating this to the 5.8S rRNA in the same lane. This 
background value was subtracted giving a final value 
referred to as the “percentage depurination.” 
 
Depurination was quantified by the following equation: 
 
% depurination = 
[(intensity of aniline fragment / intensity of 5.8S rRNA) x 
(160 / 369)]  
x 100 - background 
 
In order to compare the activities of RTA-peptide fusions 
with wild-type RTA, a value of the concentration of protein 
required for 50% depurination (D50) was calculated with 
35% depurination being half of the maximal depurination. It 
is of interest to note that RTA never produces a 100% 
dupurination of yeast ribosomes, reaching only a 70% level. 
This lack of complete dupurination is thought to be due to 
the different conformations that the ribosome adopts during 
protein synthesis resulting in a small proportion of 
ribosomes that are refractory to N-glycosidase activity (12). 
 
(f) Preparation of Kirby reagent 
 
6 g of 4-amino salicylic acid (sodium salt) was dissolved in 
25 ml of 200 mM Tris.Cl, pH 7.6 / 40 mM KCl and to this 
10 ml of 10% tri-isopropylnapthalene sulphonic acid was 
added. Tris-saturated phenol was added until the solution 
was no longer cloudy. The volume was made up to 50 ml 
with sterile distilled water and the solution was stored at -
20ºC. 
 
(g) Preparation of acetic-aniline reagent. 
 
0.5 ml of glacial acetic acid was mixed with 7 ml of sterile 
distilled water and 1 ml of redistilled aniline. The pH was 
adjusted to 4.5 with glacial acetic acid and the solution was 
made up to 11 ml with sterile distilled water. Aniline reagent 
was stored at 4ºC in the dark. 
 
Preparation of yeast ribosomes 
 
A single colony of yeast strain ABYS1 was grown for 24 
hours at 30ºC at 250 rpm in YPD medium (1% (w/v) yeast 
extract, 2% (w/v) bactopeptone, 2% (w/v) glucose) 
supplemented with 1 ml of 0.2% adenine and 0.2% uracil per 
100 ml of media. 
  
500 ml of YPD medium (supplemented with adenine and 
uracil) was inoculated with this 10 ml culture and grown for 
12 hours at 30ºC at 250 rpm in an orbital shaker. Cells were 
harvested by centrifugation in a JA10 rotor in a Beckman J2-
21M/E centrifuge at 2740 xg (5000 rpm) at 4ºC for 5 
minutes. Cell pellets were washed 3 times by resuspending Smith et al.   16 
 
 
Biological Procedures Online • Vol. 5 No. 1 • February 17, 2003 • www.biologicalprocedures.com 
in 100 ml of deionized, sterile water and centrifuging again 
at 2740 xg (5000 rpm) at 4ºC for 5 minutes. After these 3 
washes, the cell pellet was resuspended in 3 pellet volumes 
of lysis buffer (100 mM KOAc, 2 mM Mg(OAc)2, 20% (v/v) 
glycerol, 20 mM Hepes/KOH pH7.4) containing PMSF at a 
final concentration of 100 mM, and transferred to oakridge 
tubes. An equal volume of acid-washed glass beads was 
added and cells were lysed by vigorous vortexing at 4ºC for 
4 to 5 minutes. Beads were pelleted by centrifugation at 750 
xg (1250 rpm) in a Beckman GPR centrifuge (GH3.7 rotor) 
for 5 minutes and the supernatant was placed into a fresh 
oakridge tube without disturbing the bead pellet. Cell debris 
was then pelleted by centrifugation in a JA20 rotor in a 
Beckman J2-21M/E centrifuge at 31400 xg  (20000 rpm) at 
4ºC for 20 minutes. The supernatant was placed into 3 ml 
polycarbonate thick walled ultracentrifuge tubes and 
ribosomes were pelleted by centrifugation at 386000 xg 
(100000 rpm) in a Beckman TLA 100.3 rotor. The 
supernatants were discarded and the pellets were rinsed 
twice with 100µl of 1x Endo buffer (25 mM Tris.Cl (pH 
7.6), 25 mM KCl, 5 mM MgCl2) before resuspending in a 
final volume of 500 µl of 1x Endo buffer. 
 
The concentration of ribosomes was estimated by measuring 
the A260 (an A260 of 25 is equal to 2 mg/ml ribosomes), 
before storing in aliquots at 20 µg/µl at -70ºC. 
 
Cytotoxicity assay 
 
MC57 target cells were plated out in a volume of 100 µl in 
96 well plates at a density of 1.5 x 10
5 cells/ml and overlaid 
with a further 100 µl of RPMI (5% FCS/2 mM glutamine) 
before incubating for 16 hours (overnight) at 37ºC. The 
medium was removed and wells were gently washed with 
sterile PBS. 100 µl of each toxin dilution in RPMI (5% 
FCS/2 mM glutamine) was added to each well in 
quadruplicate. The plates were incubated for 4 hours at 37ºC 
after which the toxin was removed and the wells were gently 
washed with sterile PBS. 
 
Protein synthesis was measured by incubating the plates at 
37ºC in the presence of 1 µCi of [
35S] methionine in 50 µl of 
PBS per well. After 90 minutes, the plates were washed three 
times with ice-cold 5% trichloroacetic acid in order to 
precipitate labelled proteins. The plates were washed a 
further 3 times with ice-cold PBS and 200 µl of scintillant 
(OptiPhase “Supermix”) was added to each well. Each plate 
was sealed and shaken for 5 minutes before counting in a 
Wallac 1450 MicroBeta Trilux liquid scintillation counter. 
 
Background radioactivity, from wells containing media only 
was deducted  from each value and the level of protein 
synthesis was calculated as a percentage of toxin-free control 
cells. 
 
Molecular Mass determination of RTA-peptide 
fusions by Mass Spectrometry 
 
Purified RTA-peptide fusions were dialysed against 5 mM 
ammonium bicarbonate (Sigma) pH 6.7, and concentrated to 
a final RTA concentration of 20 mM in a Centricon 10 
(Amicon). The molecular mass of the fusion was determined 
by electrospray ionization mass spectrometry (Proteomics 
Facility, University of Warwick). 
 
RESULTS AND DISCUSSION 
 
We created a genetic fusion of DNA for the H-2D
b-restricted 
influenza nucleoprotein NP 366-374 peptide 
(ASNENMDAM) (13) to the 5’ end of the cDNA encoding a 
catalytic site mutant (R180H) of RTA (14). Potential clones 
were fully sequenced to confirm the presence of the fused 
DNA. The fusion protein, termed nNP-RTA, was expressed 
in, and purified from E. coli JM101. The expression vector 
has been previously used to generate a high yield (10-20 mg) 
of soluble RTA protein (10,12,14).  
 
RTA expression was induced in mid-log cultures, grown in 
2YT medium at 30°C, with the addition of IPTG. Various 
concentrations of IPTG were tested; strong induction was 
obtained with 0.1 mM IPTG, resulting in a total yield of 
soluble nNP-RTA of 8-15 mg/L of bacterial culture.  
 
Following sonication of the bacterial cell pellet in 5 mM 
sodium phosphate buffer (pH 6.5), the nNP-RTA fusion was 
purified from the soluble fraction by ion exchange 
chromatography using a cation exchange matrix. After 
binding, the column was first washed in buffer containing 
100 mM NaCl, then a linear gradient (100 mM - 300 mM 
NaCl) was applied to the column, and collected in 10 ml 
fractions (Fig. 1). The nNP-RTA eluted in 115 mM - 185 
mM NaCl (fractions 4-22; Fig. 1), to a purity of 
approximately 90%. Western blot analysis using antibodies 
directed against RTA confirmed the identity of the fusion 
(data not shown). Further purification at this stage was not 
needed, as following specific reassociation of the nNP-RTA 
with RTB, the resulting holotoxin was then separated away 
from any contaminants (see below).  
 
Interestingly however, purification repeatedly showed two 
species of the fusion protein, a slower migrating form (Fig. 
1, nNP-RTA) and a faster migrating band (Fig. 1, RTA*). 
The presence of protease inhibitors in the initial sonication 
buffer, and during the 100 mM NaCl wash, increased the 
relative proportion of the higher band seen on elution (data 
not shown).  
 
 
Fig. 1: Purification of nNP-RTA. Fractions obtained from the linear salt 
gradient used to elute the fusion protein from the cation exchange matrix were 
resolved by reducing SDS-PAGE (15%), and stained with coomassie blue. The 
prominent band at ∼34 kDa corresponds to the nNP-RTA protein (doublet). 
Fractions 4-18 show the higher molecular weight nNP-RTA, whilst fractions 
12-22 show the nNP-cleaved RTA (RTA*). 
 Smith et al.   17 
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In order to characterize the chimera, both the early fractions 
(4-12), containing predominantly the higher band, and the 
later fractions (14-22) were separately pooled and 
concentrated. The proteins were dialysed into a volatile 
buffer (5 mM ammonium bicarbonate pH 6.7) and their 
respective molecular masses were determined by mass 
spectrometry (electrospray ionization).  The slower 
migrating, higher band produced a clean multiple charge 
series (Fig. 2, insert), which when deconvoluted gave a 
calculated molecular mass of 30854.8 (±0.3) daltons (Fig. 2, 
main). The experimental value was in agreement with the 
predicted theoretical mass for nNP-RTA of 30854.83 daltons 
(http://www.expasy.ch/tools/pi_tool.html), confirming the 
upper band was indeed nNP-RTA. The lower band gave an 
experimental mass that corresponded to the predicted mass 
of wild type RTA (data not shown), indicating that the NP 
peptide had been cleaved from the RTA fusion at some time 
during cell lysis and/or purification. Only the full size fusion 
was used for further analysis and antigen presentation 
studies. 
 
 
Fig. 2: The nNP-peptide is present in the fusion vector. nNP-RTA was 
analyzed by electrospray ionization mass spectrometry. The multiple charged 
series (insert) is shown. The deconveluted spectra (main) shows the molcular 
mass of the nNP-RTA fusion (30854.8 ±0.3 daltons). 
 
However, once purified the nNP-RTA fusion remained 
stable (stored at -20°C in PBS containing 15% glycerol) for 
up to 6 months with no further cleavage of the peptide or 
degradation of the complete fusion (data not shown). 
 
The rRNA-specific N-glycosidase activity of the nNP-RTA 
fusion towards isolated yeast ribosomes was determined to 
be 380 fold lower than that of wild-type RTA (Fig. 3). The 
reduction in activity of nNP-RTA could be solely attributed 
to the presence of the active site substitution R180H, known 
to reduce enzymatic activity by 400-750 fold (14), and not 
the presence of the NP peptide. Indeed, a wild type RTA 
fusion with the NP peptide exhibited the same catalytic 
activity as the native toxin (data not shown). Taken together, 
these data indicate that the NP peptide does not affect the 
function of the RTA portion of the fusion, implying that the 
structure of the fusion, as compared to wild type RTA, was 
not significantly altered. 
 
 
Fig. 3: N-glycosidase activity of nNP-RTA compared to wild type RTA. 
Isolated yeast ribosomes (20 µg) were incubated with increasing nNP-RTA or 
wild type RTA for 60 minutes at 30ºC. rRNA was isolated and 4 µg was 
aniline-treated and electrophoresed on an agarose/formamide gel. rRNAs were 
quantified from digital images using Imagequant software (A). The 
depurination was calculated by relating the amounts of the aniline-fragment 
(A; arrowhead) and the 5.8S rRNA and expressed as a percentage. A toxin-
incubated non-aniline treated control is shown (N/A). A graphical 
representation of the depurination calculated for RTA (z) and nNP-RTA () 
is shown (B). Symbols indicate the experimental data; error bars represent the 
standard deviation of at least 2 experiments and solid lines represent best-fitted 
curves. 
 
To enable intercellular delivery of the NP peptide, the fusion 
protein must be reassociated with the galactose-specific 
lectin RTB. The holotoxin can then bind to and enter cells 
via receptor-mediated endocytosis.  Equal amounts (100 µg) 
of nNP-RTA and plant-derived RTB were mixed in the 
presence of the reducing agent β-mercaptoethanol in PBS 
containing 100 mM lactose, dialysed first against PBS 
containing 100 mM lactose for 16 hours, then against PBS 
for 36 hours. Un-reassociated RTB is moderately labile, and 
therefore forms homodimers to aid stability, however such 
dimers would impair any association with nNP-RTA. The 
presence of reducing agent and the lactose in the buffer was 
shown to increase the efficiency of reassociation from 12% 
to 25-35%. Such an increase in efficiency could have 
occurred by disulphide-bond reduction of any RTB dimers 
that may have been present and subsequent stabilization of 
monomeric RTB by the presence of the lactose. 
 
Reassociated nNP-ricin was purified by affinity 
chromatography using immobilized α-lactose. Only Smith et al.   18 
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reassociated holotoxin and non-associated RTB will bind to 
the column through the lectin activity of the B chains. 
Extensive washing with PBS removes any free nNP-RTA, 
and other contaminants. The nNP-ricin, and any non-
associated B-chain, was then eluted from the column by 
competition with 75 mM galactose. The presence of non-
associated RTB in the sample was shown not to affect the 
binding, routing or toxicity of wild type holotoxin, indeed 
wild-type RTA reassociated to RTB has the same 
cytotoxicity as plant derived ricin (data not shown). The 
eluted fractions were dialysed against PBS, to remove the 
free sugar, before being concentrated and quantified. 
Reducing SDS-PAGE of the nNP-ricin (known volume, 5 
µl) was performed, along with known amounts (ng) of native 
RTA and then silver-stained (Fig. 4A). 
 
 
Fig. 4: Quantification of reasociated nNP-ricin. RTA standards (ng) along 
with 5 µl of the reassociated nNP-ricin (nNP-RTA shown by asterisk) were 
resolved by reducing SDS-PAGE (15%), and sliver stained (A). Band 
intensities were determined for the RTA standards (z) by scanning laser 
densitometry, and calibration curve plotted (B). Linear regression analysis 
produced the equation of the graph (y = 134.61x + c). Error bars represent 
percentage standard deviation from the mean. 
 
The resulting bands, corresponding to the RTA standards, 
were quantified by scanning laser desitometery, and a 
standard curve plotted (Fig. 4B). Only the bands representing 
the full-size nNP-RTA (Fig. 4A, ∗) were scanned, and the 
amount of each sample was determined using the equation of 
the graph (y = 134.61x + c, where c = 0, and y corresponds 
to the scanned value). The average value for nNP-RTA was 
then multiplied by a factor of two (since RTA and RTB have 
the same naked molecular mass), and divided by the volume 
loaded, to convert to a holotoxin concentration. As accurate 
concentration measurements were essential for the use of the 
delivery vector in mammalian cells, this quantitation 
procedure was repeated no less than 3 times.  The average 
concentration of the nNP-ricin delivery vector was 51.45 
(±1.7) µg/ml (686 nM), giving a reassociation efficiency of 
32.15%. 
 
Murine fibrosarcoma cells (MC57) were assayed for their 
sensitivity to the nNP-ricin vector in order to determine 
correct vector routing, and the therapeutic dose range (75 - 
100% cellular protein synthesis remaining) of the vector. 
MC57 cells were still sensitive to nNP-ricin, but to a lesser 
degree than wild type ricin (Fig. 5). 
 
 
Fig. 5: Sensitivity of MC57 cells challenged with either nNP-ricin or wild 
type ricin. MC57 cells (1.5 x10
4) were incubated with increasing 
concentrations of either nNP-ricin () or wild type ricin (z) for 16 hours at 
37ºC. Incorporation of [
35S]-methionine was used to determine remaining 
cellular protein synthesis, compared to untreated control cells. Error bars 
represent percentage standard deviation from the mean. 
 
The IC50 values (half maximal protein synthesis inhibition) 
for nNP-, and wild type ricin, were 6.95 (±0.44) nM and 
0.0155 (±0.0037) nM respectively, corresponding to a 467 
(±114)-fold decrease in cytotoxicity of the delivery vector. 
Such a decrease in sensitivity was consistent with the 
published data for ricin carrying a R180H substitution (14), 
again supporting the data that the NP-peptide had not altered 
the normal activity of the protein. MC57 cells were 
completely protected from nNP-ricin following treatment 
with brefeldin A (data not shown). Such a protection 
indicates a prerequisite for retrograde Golgi transit, a known 
requirement for ricin intoxication (15), suggesting that 
routing of the delivery vector is essentially the same as for 
the wild type toxin.  For delivery purposes the nNP-ricin 
vector must not heavily compromise target cell protein 
synthesis, as such, no less than 75% protein synthesis must 
still occur in the MC57 target cells. Therefore, nNP-ricin 
concentrations up to and including 6.5 nM (400 ng/ml) 
would be tolerated for delivery. It is of interest to note that 
complete attenuation of activity may not be required for such 
delivery vectors. It has been suggested that a mild toxic Smith et al.   19 
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effect resulting in a localized non-specific immune response 
could be beneficial for such vectors (4). Indeed, native 
cholera toxins from Vibrio cholerae (16), and pertussis toxin 
from Bordetella pertussis (17), have been shown to promote 
the maturation of specialized antigen presenting cells, 
leading to the activation of an immune response. 
 
In conclusion, we have characterized the nNP-ricin vector 
for use in delivery to target cells. Characterization has 
confirmed that the vector contains an attenuated catalytic 
domain to prevent target cell death, and in doing so a 
therapeutic range for the vector was determined. 
Furthermore, we have shown that the N-terminally fused 
peptide epitope remains intact following purification. The 
ricin vector can now be used in studies focusing on 
intracellular delivery, investigating specific CD8
+ 
presentation via MHC class I molecules (1). 
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